AR045656A1 - Inhibidores de gamma secretasa - Google Patents
Inhibidores de gamma secretasaInfo
- Publication number
- AR045656A1 AR045656A1 ARP040103301A ARP040103301A AR045656A1 AR 045656 A1 AR045656 A1 AR 045656A1 AR P040103301 A ARP040103301 A AR P040103301A AR P040103301 A ARP040103301 A AR P040103301A AR 045656 A1 AR045656 A1 AR 045656A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- group
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Abstract
Se describe un método de tratamiento de la Enfermedad de Alzheimer que utiliza uno o más compuestos del presente, y composiciones farmacéuticas que los comprenden. Reivindicación 1: Un compuesto de fórmula (1), o una de sus sales, solvatos o ésteres aceptables desde el punto de vista farmacéutico, en el cual: A) R1 se selecciona del grupo formado por: arilo no sustituido; arilo sustituido con uno o más grupos R5; heteroarilo no sustituido; y heteroarilo sustituido con uno o más grupos R5; B) R2 se selecciona del grupo formado por: alquilo; -XC(O)Y; -alquilen(C1-6)-XC(O)Y; -alquilen(C0-6)-cicloalquilen(C3-6)-alquilen(C0-6)-XC(O)Y; arilo; arilo sustituido con uno o más grupos R5; heteroarilo; heteroarilo sustituido con uno o más grupos R5; cicloalquilen-X-C(O)-Y; -CH2-X-C(O)-NR3-Y; -CH2-X-C(O)-Y; y -CH2-X-C(O)-NR3-Y; C) cada R3 se selecciona en forma independiente del grupo formado por: H; alquilo; -OH; -O-alquilo; acilo; aroilo; el resto (R3)2, junto con el átomo de carbono del anillo al cual se muestra unido en la fórmula (1), define un grupo carbonilo, -C(O)-, con la salvedad de que cuando m es un número entero superior a 1, como máximo un grupo carbonilo esté presente en el anillo que se muestra en la fórmula (1), halo; D) cada R3A y R3B se selecciona en forma independiente del grupo formado por: H; y alquilo; E) R5 se selecciona en forma independiente del grupo formado por: halo; -CF3; -OH; -O-alquilo; -OCF3; -CN; -NH2; -C(O)2alquilo; - C(O)NR6R7; -alquilen-NR6R7; -NR6C(O)alquilo; -NR6C(O)arilo; -NR6C(O)heteroarilo; y -NR6C(O)NR6R7; F) X se selecciona del grupo formado por: -O-; -NH-; -N-alquilo; y -O-alquileno; G) Y se selecciona del grupo formado por: 1) -NR6R7; 2) - N(R3)CH2)bNR6R7 en la que b es 2-6; 3) arilo no sustituido; 4)heteroarilo no sustituido; 5) -alquilo; -cicloalquilo; 7) arilalquilo no sustituido; 8) arilcicloalquilo no sustituido; 9) heteroarilalquilo no sustituido; 10) heteroarilcicloalquilo no sustituido; 11) arilheterocicloalquilo no sustituido; 12) arilo sustituido; 13) heteroarilo sustituido; 14) arilalquilo sustituido; 15) arilcicloalquilo sustituido; 16) heteroarilalquilo sustituido; 17) heteroarilcicloalquilo sustituido; y 18) arilheterocicloalquilo sustituido; 19) heterocicloalquil alquilo sustituido; 20) heteroaril alquil no sustituido; 21) heterocicloalquil alquil arilo no sustituido; 22) heterocicloalquilo no sustituido; y 23) cicloalquilo no sustituido, en los que el resto arilo de dichos grupos sustituidos 12), 14), 15), 18) y 21) de dicho grupo Y, y el resto heteroarilo de dichos grupos sustituidos 13), 16), 17) y 20) de dicho grupo Y, se sustituyen con uno o más sustituyentes seleccionados en forma independiente del grupo formado por: halo; -CF3; -OH; -O-alquilo; -OCF3; -CN; -NH2; -C(O)2(C1-6)alquilo; -C(O)NR6R7; -alquilen(C1-6)-NR6R7; -NR6C(O)alquilo; -NR6C(O)arilo; -NR6C(O)heteroarilo; -NR6C(O)NR6R7; y alquilo; o Y se selecciona del grupo formado por las fórmulas (2); H) R6 y R7 se seleccionan en forma independiente del grupo formado por: H; alquilo; alquilo sustituido con 1 a 4 grupos hidroxi, con la salvedad de que uno de los grupos hidroxi esté unido a un carbono al cual está unido, además, un nitrógeno; cicloalquilo; arilalquilo; heteroarilalquilo; la fórmula (3); la fórmula 4); y heterocicloalquilo; I) cada R8 se selecciona en forma independiente del grupo formado por: H; alquilo; alquilo sustituido con 1 a 4 grupos hidroxi; arilo; -OH; -O-alquilo; -C(O)O-alquilo; si r es superior a 1, por lo menos dos grupos R8, junto con el átomo o átomos de carbono del anillo al cual están unidos definen un anillo, en el cual uno o más átomos de carbono de dicho anillo pueden reemplazarse en forma independiente entre sí por -O- o -C(O)O-, y dicho anillo puede estar sustituido con 1 a 4 grupos hidroxi; J) cada R9 se selecciona en forma independiente del grupo formado por: H; alquilo; alquilo sustituido con 1 a 4 grupos hidroxi; cicloalquilo; cicloalquilo sustituido con 1 a 4 grupos hidroxi; arilalquilo; heteroarilalquilo; -C(O)O-alquilo; alquilen-O-alquilen-OH; arilo sustituido con uno o más grupos R5; heteroarilo sustituido con uno o más grupos R5; heteroarilo no sustituido; arilo no sustituido; -alquilen-C(O)O-alquilo; y hidroxialquil-O-alquilo; K) cada R10 se selecciona en forma independiente del grupo formado por: H; y alquilo; L) R11 se selecciona del grupo formado por: 1) arilo no sustituido; 2) arilo sustituido; 3) heteroarilo no sustituido; 4) alquilo; 5) cicloalquilo; 6) arilalquilo no sustituido; 7) arilcicloalquilo no sustituido; 8) heteroarilalquilo no sustituido; 9) heteroarilcicloalquilo no sustituido; 10) arilheterocicloalquilo no sustituido; 11) alcoxialquilo; 12) heteroarilo sustituido; 13) arilalquilo sustituido; 14) arilcicloalquilo sustituido; 15) heteroarilalquilo sustituido; y 16) arilheterocicloalquilo sustituido, en los que el resto arilo de dichos grupos sustituidos 2), 13), 14) y 16) de dicho grupo R11, y el resto heteroarilo de dichos grupos sustituidos 12) y 15) de dicho grupo R11, se sustituyen con uno o más sustituyentes seleccionados en forma independiente del grupo formador por: halo; -CF3; -OH; -O-alquilo; -OCF3; -CN; -NH2; -C(O)2(C1-6)alquilo; -C(O)NR6R7; -alquilen(C1-6)-NR6R7; -NR6C(O)alquilo; -NR6C(O)arilo; -NR6C(O)heteroarilo; y -NR6C(O)NR6R7; M) m es 0 a 3, y si m es mayor que 1, m restos pueden ser idénticos o diferentes entre sí; n es 0 a , y si n es mayor que 1, n restos pueden ser idénticos o diferentes entre sí; o es 0 a 3, y si o es mayor que 1, o restos pueden ser idénticos o diferentes entre sí; de modo tal que m + n + o es 1, 2, 3 ó 4; N) p es 0 a 4, y si mayor que 1, p restos pueden ser idénticos o diferentes entre sí; O) r es 0 a 4, y si mayor que 1, r restos pueden ser idénticos o diferentes entre sí; P) s es 0 a 3, y si es mayor que 1, s restos pueden ser idénticos o diferentes entre sí; y Q) Z se selecciona del grupo formado por: 1) heterocicloalquilo no sustituido; 2) heterocicloalquilo sustituido; 3) -NH2; 4) -NH(alquilo); 5) -N(alquilo)2 en el que cada alquilo es idéntico o diferente; 6) -NH(cicloalquilo no sustituido); 7) - NH(cicloalquilo sustituido); 8) -N(alquil)(cicloalquilo no sustituido); 9) -N(alquil)(cicloalquilo sustituido); 10) -NH(aralquilo no sustituido); 11) -NH(aralquilo sustituido); 12) -N(alquil)(aralquilo); 13) -NH(heterocicloalquilo no sustituido); 14) -NH(heterocicloalquilo sustituido); 15) -N(alquil)(heterocicloalquilo no sustituido); 16)-N(alquil)(heterocicloalquilo sustituido); 17) -NH(heteroaralquilo no sustituido); 18) -NH(heteroaralquilo sustituido); 19) -NH-alquilen-(cicloalquilo no sustituido); 20) -NH-alquilen-(cicloalquilo sustituido); 21) -N(alquil)alquilen-(cicloalquilo no sustituido); 22) -N(alquil)alquilen-(cicloalquilo sustituido); 23) -NHalquilen-(heterocicloalquilo no sustituido); 24) -NHalquilen-(heterocicloalquilo sustituido); 25) -N(alquil)alquilen-(heterocicloalquilo no sustituido); 26) -N(alquil)alquilen-(heterocicloalquilo sustituido); 27) heterocicloalquilo benzofusionado no sustituido; y 28) heterocicloalquilo benzofusionado sustituido; 29) H; y 30) - N(hidroxialquilo)2, en el que cada alquilo puede ser idéntico o diferente, en los que dicho resto heterocicloalquilo sustituido de los sustituyentes 2), 14), 16), 24), 26) y 27) del grupo Z, y dicho resto cicloalquilo sustituido de los sustituyentes 7), 9), 20) y 22) del grupo Z, y dicho resto arilo sustituido del sustituyente 11) del grupo Z, y dicho resto heteroarilo sustituido del sustituyente 18) del grupo Z, están sustituidos con 1 a 3 grupos seleccionados en forma independiente del grupo formado por: alquilo; -OH; -Oalquilo; -OC(O)alquilo; -OC(O)arilo; -NH2; -NH(alquilo); -N(alquilo)2 en el que cada alquilo es idéntico o diferente; -NHC(O)alquilo; -N(alquil)C(O)alquilo; -NHC(O)arilo; -N(alquil)C(O)arilo; -C(O)alquilo; -C(O)arilo; - C(O)NH2; -C(O)NH(alquilo); -C(O)N(alquilo)2 en el que cada alquilo es idéntico o diferente; -C(O)2alquilo; -alquilen-C(O)Oalquilo; piperidinilo; pirrolidinilo; 1,1-etilendioxi; arilo; heteroarilo; e -O-CH2CH2-O-, en el cual ambos átomos de oxígeno están unidos al mismo átomo de carbono, y siempre que los restos arilo y heteroarilo de dicho grupo Z no estén sustituidos con dicho grupo -O-CH2CH2-O-.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/663,042 US20040171614A1 (en) | 2002-02-06 | 2003-09-16 | Novel gamma secretase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AR045656A1 true AR045656A1 (es) | 2005-11-02 |
Family
ID=34375807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103301A AR045656A1 (es) | 2003-09-16 | 2004-09-15 | Inhibidores de gamma secretasa |
Country Status (14)
Country | Link |
---|---|
US (1) | US20040171614A1 (es) |
EP (1) | EP1663975A1 (es) |
JP (1) | JP2007519607A (es) |
KR (1) | KR20060106814A (es) |
CN (1) | CN101061097A (es) |
AR (1) | AR045656A1 (es) |
AU (1) | AU2004274449A1 (es) |
CA (1) | CA2538590A1 (es) |
IL (1) | IL174270A0 (es) |
MX (1) | MXPA06003058A (es) |
PE (1) | PE20050377A1 (es) |
TW (1) | TW200519087A (es) |
WO (1) | WO2005028440A1 (es) |
ZA (1) | ZA200602193B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7256186B2 (en) * | 2002-02-06 | 2007-08-14 | Schering Corporation | Gamma secretase inhibitors |
US20040171614A1 (en) * | 2002-02-06 | 2004-09-02 | Schering-Plough Corporation | Novel gamma secretase inhibitors |
US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
US7598250B2 (en) * | 2003-08-08 | 2009-10-06 | Schering Corporation | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent |
WO2005097768A2 (en) * | 2004-04-05 | 2005-10-20 | Schering Corporation | Novel gamma secretase inhibitors |
EP1789404B1 (en) * | 2004-06-30 | 2010-03-24 | Schering Corporation | Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors |
CN101027297B (zh) * | 2004-07-28 | 2010-09-08 | 先灵公司 | 大环β-分泌酶抑制剂 |
WO2008008720A2 (en) | 2006-07-10 | 2008-01-17 | Synapsin Pharmaceuticals, Inc. | Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing physical performance |
US9259419B2 (en) | 2006-07-10 | 2016-02-16 | Synapsin Pharmaceuticals, Inc. | Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing physical performance |
MX2009003382A (es) * | 2006-09-29 | 2009-04-08 | Gruenenthal Gmbh | Derivados de sulfonamidas sustituidos. |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
EP2117540A1 (en) | 2007-03-01 | 2009-11-18 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
ES2373253T3 (es) * | 2007-05-25 | 2012-02-01 | Elan Pharmaceuticals Inc. | Pirazolopirrolidinos como inhibidores de gamma secretasa. |
WO2009146875A1 (en) * | 2008-06-03 | 2009-12-10 | Fresenius Medical Care Deutschland Gmbh | Pharmaceutical compositions comprising gamma secretase modulators |
SG178953A1 (en) | 2009-09-11 | 2012-04-27 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
CN106831541B (zh) | 2011-11-18 | 2019-09-06 | 赫普泰雅治疗有限公司 | 毒蕈碱性m1受体激动剂 |
JP6478923B2 (ja) | 2013-02-07 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited | ムスカリンm4受容体アゴニストとしてのピペリジン−1−イル及びアゼピン−1−イルカルボキシレート |
GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
KR102669173B1 (ko) | 2017-06-30 | 2024-05-23 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 퀴놀리닐시클로헥실프로판아미드 화합물 및 그의 개선된 제조 방법 |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9804426D0 (en) * | 1998-03-02 | 1998-04-29 | Pfizer Ltd | Heterocycles |
US6589978B2 (en) * | 2000-06-30 | 2003-07-08 | Hoffman-La Roche Inc. | 1-sulfonyl pyrrolidine derivatives |
US20040171614A1 (en) * | 2002-02-06 | 2004-09-02 | Schering-Plough Corporation | Novel gamma secretase inhibitors |
TW200302717A (en) * | 2002-02-06 | 2003-08-16 | Schering Corp | Novel gamma secretase inhibitors |
-
2003
- 2003-09-16 US US10/663,042 patent/US20040171614A1/en not_active Abandoned
-
2004
- 2004-09-14 TW TW093127793A patent/TW200519087A/zh unknown
- 2004-09-14 PE PE2004000889A patent/PE20050377A1/es not_active Application Discontinuation
- 2004-09-15 AR ARP040103301A patent/AR045656A1/es unknown
- 2004-09-15 MX MXPA06003058A patent/MXPA06003058A/es not_active Application Discontinuation
- 2004-09-15 EP EP04784148A patent/EP1663975A1/en not_active Withdrawn
- 2004-09-15 KR KR1020067005286A patent/KR20060106814A/ko not_active Application Discontinuation
- 2004-09-15 AU AU2004274449A patent/AU2004274449A1/en not_active Abandoned
- 2004-09-15 JP JP2006526994A patent/JP2007519607A/ja active Pending
- 2004-09-15 CA CA002538590A patent/CA2538590A1/en not_active Abandoned
- 2004-09-15 WO PCT/US2004/030191 patent/WO2005028440A1/en active Application Filing
- 2004-09-15 CN CNA2004800335264A patent/CN101061097A/zh active Pending
-
2006
- 2006-03-12 IL IL174270A patent/IL174270A0/en unknown
- 2006-03-15 ZA ZA200602193A patent/ZA200602193B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2007519607A (ja) | 2007-07-19 |
ZA200602193B (en) | 2007-09-26 |
WO2005028440A1 (en) | 2005-03-31 |
MXPA06003058A (es) | 2006-05-31 |
TW200519087A (en) | 2005-06-16 |
EP1663975A1 (en) | 2006-06-07 |
PE20050377A1 (es) | 2005-05-30 |
CA2538590A1 (en) | 2005-03-31 |
KR20060106814A (ko) | 2006-10-12 |
AU2004274449A1 (en) | 2005-03-31 |
US20040171614A1 (en) | 2004-09-02 |
IL174270A0 (en) | 2006-08-01 |
CN101061097A (zh) | 2007-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR045656A1 (es) | Inhibidores de gamma secretasa | |
AR038482A1 (es) | Inhibidores de la gamma secretasa | |
AR038843A1 (es) | Derivados de fenetanolamina para el tratamiento de enfermedades respiratorias | |
AR049377A1 (es) | Inhibidores de secretasa gamma | |
AR041009A1 (es) | Compuestos heterociclicos nitrogenados que presentan actividad inhibitoria contra la integrasa del vih | |
TW200612920A (en) | Novel imidazolidine derivatives | |
CO5580746A2 (es) | Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina | |
CO5560575A2 (es) | Compuestos derivados de dihidro-pteridinonas caracterizados por ser inhibidores de especificas cinasas del ciclo celular y preparaciones farmaceuticas que los contienen | |
AR054208A1 (es) | Derivados de oxopiperidina, su preparacion, una composicion farmaceutica y compuestos intermediarios | |
HUP0302526A2 (hu) | Makrolid vegyületek, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
HUP0302956A2 (hu) | Tioflavinszármazékok az Alzheimer-kór antemortem diagnózisában történő alkalmazásra, eljárás a vegyületek előállítására és ezeket tartalmazó gyógyszerkészítmények | |
PA8795301A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
AR036106A1 (es) | Compuestos azaindoles inhibidores de quinasa selectivos, composiciones farmaceuticas y el uso de dicha composicion para la fabricacion de un medicamento | |
EP2258711A3 (en) | New forms of 5-azacytidine | |
RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
CO5570669A2 (es) | Pirazolopirimidinas como agentes terapeuticos | |
NO20052469L (no) | Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2. | |
PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
AR057986A1 (es) | Compuesto heterociclico y su uso farmaceutico | |
CY1109220T1 (el) | Παραγωγα ν-ακυλαμινοβενζολιου ως εκλεκτικοι αναστολεις της οξειδασης μονοαμινης β | |
AR009413A1 (es) | Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende | |
MY134083A (en) | Crystalline clindamycin free base | |
RU2005137032A (ru) | Применение оксазолидинон-хинолиновых гибридных антибиотиков для лечения сибирской язвы и других инфекций | |
AR069185A1 (es) | Compuestos heterociclicos moduladores de gamma secretasa, composiciones farmaceuticas que los contienen y usos de los mismos para tratar trastornos del snc, tales como enfermedad de alzheimer y otras relacionadas con la deposicion de proteinas amiloides. | |
DK0521827T3 (da) | Farmakologisk virksomme hydrazinderivater og fremgangsmåde til deres fremstilling |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |